NEULASTA

This brand name is authorized in United States. It is also authorized in Australia, Austria, Canada, Croatia, Cyprus, Estonia, Finland, France, Ireland, Italy, Lithuania, Netherlands, Poland, Romania, Spain, UK.

Active ingredients

The drug NEULASTA contains one active pharmaceutical ingredient (API):

1	Pegfilgrastim UNII 3A58010674 - PEGFILGRASTIM
	Pegfilgrastim is a sustained duration form of filgrastim due to decreased renal clearance. Pegfilgrastim and filgrastim have been shown to have identical modes of action, causing a marked increase in peripheral blood neutrophil counts within 24 hours, with minor increases in monocytes and/or lymphocytes.
	Read more about Pegfilgrastim

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L03AA13	Pegfilgrastim	L Antineoplastic and immunomodulating agents → L03 Immunostimulants → L03A Immunostimulants → L03AA Colony stimulating factors
Discover more medicines within L03AA13

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	6363X, 9514R
CA	Health Products and Food Branch	02249790
EE	Ravimiamet	1195893, 1308721
ES	Centro de información online de medicamentos de la AEMPS	02227004
FI	Lääkealan turvallisuus- ja kehittämiskeskus	056936
FR	Base de données publique des médicaments	68735818
GB	Medicines & Healthcare Products Regulatory Agency	354849, 91203
IE	Health Products Regulatory Authority	88484
IT	Agenzia del Farmaco	035716012, 035716024, 035716036, 035716048
LT	Valstybinė vaistų kontrolės tarnyba	1029471, 1029472, 1029473, 1056554, 1085264
NL	Z-Index G-Standaard	15007219
NL	Z-Index G-Standaard, PRK	68756
PL	Rejestru Produktów Leczniczych	100126910
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W51563001
US	FDA, National Drug Code	55513-190